论文部分内容阅读
为观察动脉粥样硬化性疾病患者血浆纤溶活性的变化及其与血脂的关系，本实验分别采用发色底物法、酶联免疫吸附测定法和酶法对３１例动脉硬化性疾病患者血浆纤溶活性和血脂水平进行了测定，并对它们的相关性进行了分析。结果发现动脉粥样硬化患者止浆Ⅰ型纤溶酶原激活剂抑制物活性较对照组开高（１２．５０±５．０６比６．９３±３．８２ｋＡＵ／Ｌ，Ｐ＝０．００３１）；组织型纤溶酶原激活剂含量增加（８．９４±３．５３比５．３６±２．３３μｇ／Ｌ，Ｐ＝０．０００１）。血浆纤溶成分与血脂相关性分析表明：Ⅰ型纤溶酶原激活荆抑制物活性与总胆固醇、甘油三酯、低密度脂蛋白胆固醇呈正相关（ｒ＝０．３２７，Ｐ＝０．０１０１）。结果提示，动脉粥样硬化患者血浆纤溶活性下降是由于Ⅰ型纤溶酶原激活剂抑制物活性增高所致，高血脂可通过使Ⅰ型纤溶酶原激活荆抑制物合成分泌增加而影响血浆纤溶活性。
In order to observe the changes of plasma fibrinolytic activity in patients with atherosclerotic disease and its relationship with serum lipids, the chromogenic substrate method, enzyme-linked immunosorbent assay and enzyme-linked immunosorbent assay were used in 31 patients with arteriosclerotic disease Fibrinolytic activity and blood lipid levels were measured, and their correlation was analyzed. The results showed that atherosclerosis patients with type Ⅰ plasminogen activator inhibitor activity than the control group was higher (12.50 ± 5.06 vs 6.93 ± 3.82 kAU / L, P = 0.0031) ; Tissue plasminogen activator content increased (8.94 ± 3.53 vs. 5.36 ± 2.33 μg / L, P = 0.0001). The correlation between plasma fibrinolysis and plasma lipids showed that the activity of type I plasminogen activator inhibitor was positively correlated with total cholesterol, triglyceride and low density lipoprotein cholesterol (r = 0.327, P = 0.0101) . The results suggest that the decline of plasma fibrinolytic activity in atherosclerotic patients is due to the increased activity of inhibitors of type I plasminogen activator. Hyperlipidemia may be affected by the increased production of type I plasminogen activator inhibitor Plasma fibrinolytic activity.